Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.
American College of Cardiology 2013
At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation resulted in no major post-procedural complications.
Patients treated with Xarelto (rivaroxaban; Janssen) for deep vein thrombosis (DVT) had less frequent hospital admissions than those treated with standard low molecular weight heparin (LMWH) and warfarin, according to study data presented at the Hospital Medicine 2015 Congress.
Boston Scientific announced that the Food and Drug Administration (FDA) has approved WATCHMAN Left Atrial Appendage Closure Device to reduce the risk of stroke in high-risk patients with non-valvular atrial fibrillation who are looking for an alternative to long-term warfarin therapy.
Co-treatment with proton-pump inhibitors (PPIs) in patients initiating warfarin was associated with reduced reduced risk of warfarin-related upper gastrointestinal (GI) bleeding, a study published in Gastroenterology reported.
A retrospective cohort study in the Annals of Pharmacotherapy found a clinically significant decrease in warfarin dose-response with concurrent hepatitis C treatments, especially with ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV-PTV/r-DSV).
A study published in JAMA found that warfarin use to prevent strokes in atrial fibrillation may not adequately manage blood clotting over time, despite patients having been stable on the drug.
AHA 2017 Scientific Sessions
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).